ZSCAN9: A Potential Drug Target and Biomarker for Cell Proliferation Inhibition

Target Name: ZSCAN9

NCBI ID: G7746

ZSCAN9

ZSCAN9: A Potential Drug Target and Biomarker for Cell Proliferation Inhibition

The rapid development of cancer has become one of the major public health concerns in the past few decades. The primary cause of cancer is the uncontrolled cell proliferation, which leads to the formation of tumors. Therefore, the discovery of new biomarkers and potential drug targets is crucial for the prevention and treatment of cancer. In this article, we discuss ZSCAN9, a cell proliferation-inducing protein 12, as a potential drug target and biomarker for cell proliferation inhibition.

ZSCAN9: A Putative Cell Proliferation-Inducing Protein

ZSCAN9 is a 12-kDa protein that was first identified using a combination of biochemical, cellular, and bioinformatic approaches. The protein is expressed in various tissues and cells, including human tissues, cancer cells, and normal cells. ZSCAN9 has been shown to induce cell proliferation in various cell types, including cancer cells, neurotumors, and stem cells.

The mechanism of ZSCAN9-induced cell proliferation is not well understood, but it is thought to involve the inhibition of cell apoptosis and the activation of cell signaling pathways that promote cell proliferation. ZSCAN9 has been shown to induce the expression of genes involved in cell cycle progression, DNA replication, and cell survival.

ZSCAN9 as a Potential Drug Target

The potential drug targets for ZSCAN9 are numerous and varied. One of the primary targets is the inhibition of cell proliferation. Since ZSCAN9 is known to induce cell proliferation, it may be a useful target for cancer therapies. The inhibition of ZSCAN9 could lead to the inhibition of tumor growth and the regression of established tumors.

Another potential drug target for ZSCAN9 is the inhibition of angiogenesis, which is the process by which new blood vessels are formed to supply oxygen and nutrients to tumors. The deregulation of angiogenesis is a key feature of cancer development, and the inhibition of ZSCAN9 may be a useful target for cancer therapies.

In addition to these targets, ZSCAN9 may also be a potential biomarker for the diagnosis and monitoring of cancer. The expression of ZSCAN9 is highly sensitive to various treatments, including chemotherapy, radiation therapy, and anti-angiogenic drugs. Therefore, the quantification of ZSCAN9 expression may be a useful biomarker for the diagnosis and monitoring of cancer.

Conclusion

In conclusion, ZSCAN9 is a promising protein that can be targeted as a potential drug or biomarker for cell proliferation inhibition in cancer cells. The inhibition of ZSCAN9-induced cell proliferation and angiogenesis may be a useful target for cancer therapies. Furthermore, the quantification of ZSCAN9 expression may be a useful biomarker for the diagnosis and monitoring of cancer. Further studies are needed to fully understand the role of ZSCAN9 as a potential drug target and biomarker for cancer.

Protein Name: Zinc Finger And SCAN Domain Containing 9

Functions: May be involved in transcriptional regulation

The "ZSCAN9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZSCAN9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets